COVID-19

[Immunological Reviews] The disease ranges in severity from asymptomatic through to severe acute respiratory distress requiring intensive care treatment and mechanical ventilation, which can lead to respiratory failure and death.

[Science Advances] Using Syrian hamsters that modeled moderate to severe COVID-19 disease, the authors demonstrated the high efficacy of PiN-21 to prevent and treat SARS-CoV-2 infection.

[Nature Communications] Using a comprehensive translational approach, researchers unraveled the virological and immunological responses following treatment to disentangle which COVID-19 patients may benefit and should be the focus of future studies.

[Neuroscientist] With advancement of organoid technology, brain organoids offer a promising tool for unravelling pathophysiologic clues and potential therapeutic options for neuropsychiatric complications of COVID-19.

[ACS Nano] The authors recently reported a SARS-CoV-2 human Fc-conjugated receptor-binding domain mRNA vaccine delivered via lipid nanoparticles.

[Stemedica Cell Technologies, Inc.] Stemedica Cell Technologies, Inc. announced that it has signed a Licensing Agreement with Pulthera, LLC for the rights to use, distribute and sell its MSC technologies in the treatment of COVID-19 and additional pulmonary conditions.